By
Trending Posts
Can OpenLoop’s Acquisition of Hey Revia Redefine How…
Key Highlights A Landmark Acquisition Strengthening OpenLoop’s Virtual Care Ecosystem OpenLoop, the Iowa-based telehealth infrastructure company known for…
Is the $2.5 Billion Insilico Medicine-Bora Pharmaceuticals Alliance…
Key Highlights A Landmark Alliance Bridging AI Discovery and Global Manufacturing In a move set to reshape the…
Can Sanofi’s Twin Lawsuits Against Pfizer and Moderna…
Key Highlights Two Companies, One Shared Technology Dispute Sanofi’s complaints, filed as Translate Bio Inc v. Pfizer Inc…
Pfizer’s $10 Billion Innovent Alliance: Is China Now…
Key Highlights A Broad Multidrug Alliance Built for Scale The agreement spans up to 12 programs, eight originating…
Can J&J’s Newly FDA-Approved Dual-Energy Ablation Catheter Help…
Key Highlights A Strategic Answer to Lost PFA Ground Johnson & Johnson enters the U.S. dual-energy ablation market…
J&J’s $1 Billion Firefly Bio Buy: Has Big…
Key Highlights A Novel Modality for a Notoriously Hard Target At the center of the acquisition is Firefly…
Can a Single Injection Change Everything? Novartis’s Itvisma…
Key Highlights Closing a Long-Standing Treatment Gap Itvisma’s approval extends gene replacement therapy to an SMA population that…
Can Novartis’s Up to $1.5 Billion Acquisition of…
Key Highlights A Landmark Exit for Early-Stage Science Brandon Capital’s exit from Myricx Bio represents one of its…
Can Novo Nordisk’s Newly EU-Approved Wegovy Pill Make…
Key Highlights A Landmark Shift From Injection to Tablet The European Commission’s authorization marks the first time a…
Trending Posts
Latest Stories
Inside Medicare’s First Price Cuts: What a 38–79% Discount on 10 Blockbuster Drugs Means for Biopharma’s Next Decade
A data-driven look at the first round of Medicare drug price negotiation, how it compares…
Novartis’s U.S. Pricing Reckoning: How Generic Erosion and Growth-Brand Volume Are Reshaping the Post-Entresto Story
Analysis of Novartis’s Q2 2026 U.S. performance, the mechanics of its patent-cliff pricing headwind, and…
Lilly’s U.S. Pricing Play: How Volume Economics Are Rewriting the Growth Story for Zepbound and Mounjaro
Analysis of Eli Lilly’s direct-to-consumer pricing strategy and its implications for the incretin market, patient…
With the Only FDA-Cleared Blood Test for Alzheimer’s Risk, Can Roche’s ADLM 2026 Portfolio Bring Earlier Answers to Patients 55 and Older?
Key Highlights A Landmark Showcase Addressing Healthcare’s Systemic Workforce Challenges Roche’s presence at ADLM 2026…
Gallery
